Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has recently reported promising clinical data from its ongoing studies, particularly highlighting the effective performance of Ampligen in therapeutic applications for post-COVID conditions and metastatic colorectal cancer. The positive outcomes from the Phase 2 studies serve as potential catalysts for future stock performance, indicating a strong development trajectory for its lead product. As the company moves forward with its research and development initiatives, the continued release of favorable data may enhance investor confidence and support a positive outlook for AIM ImmunoTech's financial growth.

Bears say

AIM ImmunoTech Inc reported a net loss of $3.3 million, with an earnings per share (EPS) of $(1.57), which was significantly worse than both internal and consensus estimates. In addition, the company continues to face multiple risks, including liquidity challenges, the potential failure of its product candidates in clinical trials, and difficulties in obtaining regulatory approvals—a combination that raises doubts about future commercial viability. The ongoing pressure from competition and shifting investor sentiment toward biotech stocks further exacerbates the negative outlook on the company's financial stability and growth prospects.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.